Exciting new therapy for Waldenström’s macroglobulinemia: ibrutinib plus rituximab - 101793

Spotlight
Video

Exciting new therapy for Waldenström’s macroglobulinemia: ibrutinib plus rituximab

VJHemOnc has 1608 videos Subscribe Here

Loading........
Description: Data from the exciting iNNOVATE study (NCT02165397) of ibrutinib plus rituximab for patients with Waldenström’s macroglobulinemia (WM) were presented at the 23rd congress of the European Hematology Association (EHA) 2018 press briefing, held in Stockholm, Sweden. Watch Dr Meletios Dimopoulos, of the National and Kapodistrian University of Athens School of Medicine, Athens, Greece, discusses this groundbreaking study, which could result in a new standard of care for WM.
Shared By : VJHemOnc
Posted on : 08/15/18
Added : 9 months ago
Category : Lymphoma